Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TAP311 in Healthy Subjects and Dyslipidemic Patients

NCT01487460 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

137

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemia
Healthy Volunteers

Interventions

DRUG: TAP311

Sponsor

Novartis Pharmaceuticals